-
Anti-B7-H3 ADC Tam-Peli Tops Topotecan in Phase III Study
Interim data from the TAISHAN-302 trial, presented by Prof. Li Zhang, Sun Yat-sen University Cancer Center, revealed improvements in ORR, OS, and PFS with tambotatug pelitecan versus topotecan, the standard second-line treatment for patients with relapsed SCLC.
More News from #WCLC26
-
Community-Focused Tobacco Policies Can Drive Global Gains in Lung Cancer Prevention
Dr. Babalola Faseru explains how evidence-based local tobacco initiatives can advance lung cancer prevention and, ultimately, improve patient outcomes on a global scale.
-
Opening Plenary Recognizes Recipients of the 2026 Distinguished Service Award
WCLC 2026 kicked off by honoring Drs. Luis M. Montuenga, Ross Camidge, Martin Carl Tammemägi, and Wendy Cooper for their significant scientific contributions throughout their careers.
